0001437749-22-020168 | 10-Q | XBRL Viewer | Acelrx Pharmaceuticals INC

Stockholders' Equity Note Disclosure [Text Block]

11. Stockholders’ Equity

Common Stock

ATM Agreement

The Company has entered into the ATM Agreement with Cantor, as agent, pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company’s common stock having an aggregate offering price of up to $80.0 million.

The Company did not sell any shares of common stock pursuant to the ATM Agreement for the three and six months ended June 30, 2022. For the three and six months ended June 30, 2021, the Company issued and sold approximately 3.0 million shares of common stock pursuant to the ATM Agreement, and received net proceeds of approximately $7.5 million, after deducting fees and expenses. As of June 30, 2022, the Company may offer and sell shares of the Company’s common stock having an aggregate offering price of up to $36.1 million under the ATM Agreement.

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

Note 6 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2022

Jun. 30, 2021

$ 570

$ 443

$ 1,012

$ 954

DSUVIA [Member]

444

392

886

573

DZUVEO [Member]

Non-cash Royalty [Member]

^[1]

126

270

570

392

1,012

843

Royalty [Member]

Contract and Other Collaboration [Member]

$ 0

$ 51

$ 0

$ 111

[1]	Represents sales to our partner in Europe for their expected product launch in the third quarter of 2022.

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Note 3 - Inventories, Net (Tables)

6 Months Ended

Jun. 30, 2022

Schedule of Inventory, Current [Table Text Block]

	Balance as of
	June 30, 2022		December 31, 2021
Raw materials	$	680	$	722
Work-in-process		—		159
Finished goods		221		230
Total	$	901	$	1,111

Note 9 - Liability Related to Sale of Future Royalties (Tables)

6 Months Ended

Jun. 30, 2022

Other Liabilities [Table Text Block]

	Six months ended June 30, 2022			Period from inception to June 30, 2022
Liability related to sale of future royalties — beginning balance	$	85,288		$	—
Proceeds from sale of future royalties		—			61,184
Non-cash royalty revenue		—			(1,083	)
Non-cash interest (income) expense recognized		(1,136	)		24,051
Consideration paid for termination of Royalty Monetization		(100	)		(100	)
Gain on termination of liability related to sale of future royalties		(84,052	)		(84,052	)
Liability related to sale of future royalties as of June 30, 2022	$	—		$	—

Note 5 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Tangible Asset Impairment Charges, Total	$ 4,901	$ 0	$ 4,901	$ 0
Depreciation, Total	200	$ 300	500	$ 500
Zalviso-related Assets [Member]
Tangible Asset Impairment Charges, Total	$ 4,900		$ 4,900

Note 2 - Investments and Fair Value Measurement

6 Months Ended

Jun. 30, 2022

Investments and Fair Value Measurement Disclosure [Text Block]

2. Investments and Fair Value Measurement

Investments

The Company classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). Marketable securities which have maturities beyond one year as of the end of the reporting period are classified as non-current.

The table below summarizes the Company’s cash, cash equivalents, restricted cash and short-term investments (in thousands):

	As of June 30, 2022
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Cash, cash equivalents and restricted cash:
Cash	$	2,637	$	—	$	—	$	2,637
Money market funds		1,150		—		—		1,150
Commercial paper		16,378		—		—		16,378
Total cash, cash equivalents and restricted cash		20,165		—		—		20,165

Short-term investments:
Commercial paper		7,758		—		—		7,758
Total short-term investments		7,758		—		—		7,758
Total cash, cash equivalents, restricted cash and short-term investments	$	27,923	$	—	$	—	$	27,923

	As of December 31, 2021
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Cash, cash equivalents and restricted cash:
Cash	$	1,443	$	—	$	—	$	1,443
Money market funds		2,822		—		—		2,822
Commercial paper		8,398		—		—		8,398
Total cash, cash equivalents and restricted cash		12,663		—		—		12,663

Short-term investments:
Commercial paper		29,504		—		—		29,504
Corporate debt securities		9,463		—		—		9,463
Total short-term investments		38,967		—		—		38,967
Total cash, cash equivalents, restricted cash and short-term investments	$	51,630	$	—	$	—	$	51,630

There were no other-than-temporary impairments for these securities at June 30, 2022 or December 31, 2021. No gross realized gains or losses were recognized on the available-for-sale securities and, accordingly, there were no amounts reclassified out of accumulated other comprehensive income (loss) to earnings during the three and six months ended June 30, 2022 and 2021.

As of June 30, 2022, and December 31, 2021, the contractual maturity of all investments held was less than one year.

Fair Value Measurement

The Company’s financial instruments consist of Level I and II assets and Level III liabilities. Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. For Level II instruments, the Company estimates fair value by utilizing third party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. Such Level II instruments typically include U.S. treasury, U.S. government agency securities and commercial paper. As of June 30, 2022, and December 31, 2021, the Company held a contingent put option liability associated with the Loan Agreement with Oxford, determined to be a Levell III instrument. The Company’s estimate of fair value of the contingent put option liability was determined by using a risk-neutral valuation model, wherein the fair value of the underlying debt facility is estimated both with and without the presence of the default provisions, holding all other assumptions constant. The resulting difference between the two estimated fair values is the estimated fair value of the default provisions, or the contingent put option, which is included under other long-term liabilities on the Condensed Consolidated Balance Sheets. Changes to the estimated fair value of this liability is recorded in interest income and other income, net in the Condensed Consolidated Statements of Operations. The fair value of the underlying debt facility is estimated by calculating the expected cash flows in consideration of an estimated probability of default and expected recovery rate in default and discounting such cash flows back to the reporting date using a risk-free rate.

The following table sets forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands):

	As of June 30, 2022
	Fair Value		Level I		Level II		Level III
Assets
Money market funds	$	1,150	$	1,150	$	—	$	—
Commercial paper		24,136		—		24,136		—
Total assets measured at fair value	$	25,286	$	1,150	$	24,136	$	—

Liabilities
Contingent put option liability	$	49	$	—	$	—	$	49
Total liabilities measured at fair value	$	49	$	—	$	—	$	49

	As of December 31, 2021
Assets	*Fair Value*		*Level I*		*Level II*		*Level III*
Money market funds	$	2,822	$	2,822	$	—	$	—
Commercial paper		37,902		—		37,902		—
Corporate debt securities		9,463		—		9,463		—
Total assets measured at fair value	$	50,187	$	2,822	$	47,365	$	—

Liabilities
Contingent put option liability	$	81	$	—	$	—	$	81
Total liabilities measured at fair value	$	81	$	—	$	—	$	81

The following tables set forth a summary of the changes in the fair value of the Company’s Level III financial liabilities for the three and six months ended June 30, 2022 and 2021 (in thousands):

	Three Months Ended June 30, 2022			Six Months Ended June 30, 2022
Fair value—beginning of period	$	55		$	81
Change in fair value of contingent put option associated with the Loan Agreement		(6	)		(32	)
Fair value—end of period	$	49		$	49

	Three Months Ended June 30, 2021			Six Months Ended June 30, 2021
Fair value—beginning of period	$	181		$	246
Change in fair value of contingent put option associated with the Loan Agreement		(53	)		(118	)
Fair value—end of period	$	128		$	128

There were no transfers between Level I, Level II or Level III of the fair value hierarchy during the three and six months ended June 30, 2022 and 2021.

Note 4 - Asset Acquisition (Tables)

6 Months Ended

Jun. 30, 2022

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

Consideration
Cash	$	3,536
Issuance of common stock to Lowell security holders in connection with asset acquisition		5,161
Issuance of common stock to settle Lowell’s transaction costs in connection with asset acquisition		350
Liability for issuance of 1,396,526 hold back shares to Lowell securityholders⁽¹⁾		800
Transaction costs		2,521
Total consideration	$	12,368

IPR&D Asset Acquired
Purchase price	$	12,368
Cash acquired		(3,549	)
Total IPR&D asset acquired⁽²⁾	$	8,819

Note 12 - Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Cost of goods sold	$	16	$	21	$	35	$	43
Research and development		153		200		327		381
Selling, general and administrative		584		951		1,174		1,837
Total	$	753	$	1,172	$	1,536	$	2,261

Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]

				Weighted
	Number of			*Average*
	*Restricted*			Grant Date
	Stock Units			Fair Value
Restricted stock units outstanding, January 1, 2022		1,774,376		$	1.71
Granted		1,061,826			0.40
Vested		(880,315	)		1.78
Forfeited		(313,288	)		1.29
Restricted stock units outstanding, June 30, 2022		1,642,599		$	0.91

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Number of Stock Options Outstanding			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
								(in thousands)
January 1, 2022		14,284,050		$	2.99
Granted		2,123,650			0.40
Forfeited		(552,745	)		1.37
Expired		(812,693	)		3.31
Exercised		—			—

June 30, 2022		15,042,262		$	2.67		5.8	$	—

Vested and exercisable options—June 30, 2022		10,473,947		$	3.31		4.5	$	—
Vested and expected to vest—June 30, 2022		15,042,262		$	2.67		5.8	$	—

Performance Shares [Member]

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Six months ended June 30, 2022
Expected term (in years)		6.3
Risk-free interest rate	1.6%	-	2.2%
Expected volatility		88%
Expected dividend rate		0%

Note 2 - Investments and Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale		$ 0				$ 0
Debt Securities, Available-for-Sale, Realized Gain (Loss), Total	$ 0		$ 0	$ 0	$ 0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3	$ 0		$ 0	$ 0	$ 0

Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Fair value, Beginning of period	$ 55	$ 181	$ 81	$ 246
Change in fair value of contingent put option associated with the Loan Agreement	(6)		(32)
Change in fair value of contingent put option associated with the Loan Agreement		(53)		(118)
Fair value, End of period	$ 49	$ 128	$ 49	$ 128

Note 5 - Property and Equipment, Net (Tables)

6 Months Ended

Jun. 30, 2022

Property, Plant and Equipment [Table Text Block]

	Balance as of
	June 30, 2022			December 31, 2021
Laboratory equipment	$	4,406		$	4,406
Leasehold improvements		5,838			5,838
Computer equipment and software		1,589			1,589
Construction in process		9,459			13,805
Tooling		826			826
Furniture and fixtures		250			250
		22,368			26,714
Less accumulated depreciation and amortization		(11,293	)		(10,786	)
Property and equipment, net	$	11,075		$	15,928

Note 2 - Investments and Fair Value Measurement (Tables)

6 Months Ended

Jun. 30, 2022

Cash, Cash Equivalents and Investments [Table Text Block]

	As of June 30, 2022
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Cash, cash equivalents and restricted cash:
Cash	$	2,637	$	—	$	—	$	2,637
Money market funds		1,150		—		—		1,150
Commercial paper		16,378		—		—		16,378
Total cash, cash equivalents and restricted cash		20,165		—		—		20,165

Short-term investments:
Commercial paper		7,758		—		—		7,758
Total short-term investments		7,758		—		—		7,758
Total cash, cash equivalents, restricted cash and short-term investments	$	27,923	$	—	$	—	$	27,923

	As of December 31, 2021
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Cash, cash equivalents and restricted cash:
Cash	$	1,443	$	—	$	—	$	1,443
Money market funds		2,822		—		—		2,822
Commercial paper		8,398		—		—		8,398
Total cash, cash equivalents and restricted cash		12,663		—		—		12,663

Short-term investments:
Commercial paper		29,504		—		—		29,504
Corporate debt securities		9,463		—		—		9,463
Total short-term investments		38,967		—		—		38,967
Total cash, cash equivalents, restricted cash and short-term investments	$	51,630	$	—	$	—	$	51,630

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

	As of June 30, 2022
	Fair Value		Level I		Level II		Level III
Assets
Money market funds	$	1,150	$	1,150	$	—	$	—
Commercial paper		24,136		—		24,136		—
Total assets measured at fair value	$	25,286	$	1,150	$	24,136	$	—

Liabilities
Contingent put option liability	$	49	$	—	$	—	$	49
Total liabilities measured at fair value	$	49	$	—	$	—	$	49

	As of December 31, 2021
Assets	*Fair Value*		*Level I*		*Level II*		*Level III*
Money market funds	$	2,822	$	2,822	$	—	$	—
Commercial paper		37,902		—		37,902		—
Corporate debt securities		9,463		—		9,463		—
Total assets measured at fair value	$	50,187	$	2,822	$	47,365	$	—

Liabilities
Contingent put option liability	$	81	$	—	$	—	$	81
Total liabilities measured at fair value	$	81	$	—	$	—	$	81

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Three Months Ended June 30, 2022			Six Months Ended June 30, 2022
Fair value—beginning of period	$	55		$	81
Change in fair value of contingent put option associated with the Loan Agreement		(6	)		(32	)
Fair value—end of period	$	49		$	49

	Three Months Ended June 30, 2021			Six Months Ended June 30, 2021
Fair value—beginning of period	$	181		$	246
Change in fair value of contingent put option associated with the Loan Agreement		(53	)		(118	)
Fair value—end of period	$	128		$	128

Payments to Acquire Businesses, Gross

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Note 4 - Asset Acquisition - Consideration for Acquisition (Details) - Lowell Therapeutics [Member]
$ in Thousands

Jan. 07, 2022

USD ($)

$ 3,536

Business Combination, Consideration Transferred, Equity Interests Issued and Issuable

6,000

Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Value

800

^[1]

Business Acquisition, Transaction Costs

2,521

Business Combination, Consideration Transferred, Total

12,368

Cash acquired

(3,549)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total

8,819

^[2]

Common Stock [Member]

Business Combination, Consideration Transferred, Equity Interests Issued and Issuable

5,161

Common Stock to Settle Transaction Costs [Member]

Business Combination, Consideration Transferred, Equity Interests Issued and Issuable

$ 350

[1]	Recorded as Other long-term liabilities in the Condensed Consolidated Balance Sheets.
[2]	Recorded as In-process research and development asset in the Condensed Consolidated Balance Sheets.

Note 3 - Inventories, Net - Inventory Components (Details) - USD ($)
$ in Thousands

Jun. 30, 2022

Dec. 31, 2021

Raw materials

$ 680

$ 722

Work-in-process

159

Finished goods

221

230

Total

$ 901

$ 1,111

^[1]

[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 7 - Long-term Debt (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Aug. 01, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	May 30, 2019
Amortization of Debt Discount (Premium)				$ 250	$ 430
Total Obligation Under Leasehold Agreement		$ 500		500
Leasehold Improvements, Gross		$ 1,700		$ 1,700		$ 1,700
Site Readiness Agreement [Member]
Debt Instrument, Periodic Payment, Principal	$ 500
Total Obligation Under Leasehold Agreement						500
Debt Instrument, Interest Rate, Effective Percentage		14.40%		14.40%
Warrant In Connection with Oxford Finance Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							176,679
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 2.83
Loan Agreement with Oxford Finance LLC [Member]
Debt Instrument, Face Amount							$ 25,000
Debt Instrument, Covenant, Minimum Required Unrestircted Cash							$ 5,000
Long-Term Debt, Total		$ 9,400		$ 9,400		$ 13,300
Interest Expense, Debt, Total		300	$ 600	700	1,200
Amortization of Debt Discount (Premium)		$ 100	$ 200	$ 200	$ 400

Note 1 - Organization and Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands

Jun. 30, 2022

Dec. 31, 2021

Jun. 30, 2021

Dec. 31, 2020

Cash and cash equivalents

$ 15,165

$ 7,663

^[1]

$ 21,327

$ 22,274

Restricted cash

5,000

^[1]

Restricted cash, net of current portion

5,000

^[1]

5,000

Total cash, cash equivalents, and restricted cash

$ 20,165

$ 12,663

$ 26,327

$ 27,274

[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 6 - Revenue From Contracts With Customers (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Contract with Customer, Liability, Total	$ 1,208	$ 1,237	$ 0	$ 49
DZUVEO [Member] \| Aguettant [Member]
Contract with Customer, Liability, Total	1,200
Contract with Customer, Liability, Current	$ 100

Note 12 - Stock-based Compensation - Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Restricted stock units outstanding (in shares) \| shares	1,774,376
Restricted stock units weighted average outstanding (in dollars per share) \| $ / shares	$ 1.71
Granted (in shares) \| shares	1,061,826
Weighted average grant date fair value, granted (in dollars per share) \| $ / shares	$ 0.40
Vested (in shares) \| shares	(880,315)
Weighted average grant date fair value, vested (in dollars per share) \| $ / shares	$ 1.78
Forfeited (in shares) \| shares	(313,288)
Weighted average grant date fair value, forfeited (in dollars per share) \| $ / shares	$ 1.29
Restricted stock units outstanding (in shares) \| shares	1,642,599
Restricted stock units weighted average outstanding (in dollars per share) \| $ / shares	$ 0.91

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net income (loss)	$ 61,989	$ (18,807)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-cash royalty revenue related to royalty monetization	0	(83)
Non-cash interest income on liability related to royalty monetization	(1,136)	(1,581)
Depreciation and amortization	881	1,029
Non-cash interest expense related to debt financing	250	430
Stock-based compensation	1,536	2,261
Non-cash gain on termination of liability related to royalty monetization	(84,152)	0
Impairment of property and equipment	4,901	0
Other	(7)	(61)
Changes in operating assets and liabilities:
Accounts receivable	(204)	531
Inventories	201	143
Prepaid expenses and other assets	(212)	(277)
Accounts payable	286	(65)
Accrued liabilities	(1,582)	(963)
Operating lease liabilities	(402)	(563)
Deferred revenue	(29)	(49)
Net cash used in operating activities	(17,680)	(18,055)
Cash flows from investing activities:
Purchase of property and equipment	(158)	(1,615)
Purchase of investments	(7,369)	(38,201)
Cash paid for asset acquisition, net of cash acquired	(1,687)	0
Proceeds from maturities of investments	38,562	24,784
Net cash provided by (used in) investing activities	29,348	(15,032)
Cash flows from financing activities:
Payment of long-term debt	(4,166)	(4,167)
Net proceeds from issuance of common stock in connection with equity financings	0	36,360
Net proceeds from issuance of common stock through equity plans	58	196
Payment of employee tax obligations related to vesting of restricted stock units	(58)	(249)
Net cash (used in) provided by financing activities	(4,166)	32,140
Net increase in cash, cash equivalents and restricted cash	7,502	(947)
Cash, cash equivalents and restricted cash—Beginning of period (See reconciliation in Note 1)	12,663	27,274
Cash, cash equivalents and restricted cash—End of period (See reconciliation in Note 1)	20,165	26,327
NONCASH INVESTING ACTIVITIES:
Purchases of property and equipment in accounts payable and accrued liabilities	1,464	839
Liability for held back shares in connection with asset acquisition in other long-term liabilities	800	0
Issuance of common stock in connection with asset acquisition	5,511	0
Establishment of right-of-use asset and lease liability	$ 85	$ 0

Note 9 - Liability Related to Sale of Future Royalties (Details Textual) - USD ($) $ in Thousands			3 Months Ended		6 Months Ended		78 Months Ended
	May 31, 2022	Sep. 18, 2015	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022
Proceeds From Sale of Royalty and Milestone Rights		$ 65,000
Consideration Paid for Termination of Royalty Monetization	$ 100				$ 100		$ 100
Gain on Termination of Liability Related to Sale of Future Royalties	$ 84,100				$ 84,152	$ (0)
Effective Annual Interest Rate			3.20%	3.60%	3.20%	3.60%
SWK [Member]
Percentage of Royalties and Rights Under Agreement		75.00%
SWK [Member] \| First Four Commercial Milestones [Member]
Percentage of Royalties and Rights Under Agreement		80.00%
Commercial Milestones Value Maximum Amount Available		$ 35,600
AcelRX [Member] \| First Four Commercial Milestones [Member]
Commercial Milestones Value Maximum Amount Available		$ 44,500

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

Business Description of Entity [Policy Text Block]

The Company

AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on July 13, 2005 as SuRx, Inc. The Company subsequently changed its name to AcelRx Pharmaceuticals, Inc. The Company’s operations are based in Hayward, California.

AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA®(known as DZUVEO® in Europe) and Zalviso® areboth focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, exclusively for use in medically supervised settings. On November 2, 2018, the U.S. Food and Drug Administration, or FDA, approved DSUVIA for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The commercial launch of DSUVIA in the United States occurred in the first quarter of 2019. In June 2018, the European Commission, or EC, granted marketing approval of DZUVEO for the management of acute moderate to severe pain in adults in medically monitored settings. AcelRx is further developing a distribution capability and commercial organization to continue to market and sell DSUVIA in the United States. In geographies where AcelRx decides not to commercialize products by itself, the Company may seek to out-license commercialization rights. The Company currently intends to commercialize and promote DSUVIA/DZUVEO outside the United States with one or more strategic partners, and, in July 2021, entered into a License and Commercialization Agreement with Laboratoire Aguettant, or Aguettant, for Aguettant to commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom, or the DZUVEO Agreement. Zalviso was approved in Europe and was commercialized by Grünenthal GmbH, or Grünenthal, through May 12, 2021 (see Termination of Grünenthal Agreements below). In July 2022, the European Marketing Authorization for Zalviso was withdrawn. In July 2021, the Company also entered into a separate License and Commercialization Agreement with Aguettant pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing 10 ml of a solution of 50 mcg/ml phenylephrine hydrochloride for injection. On January 7, 2022, the Company closed the definitive merger agreement dated as of November 14, 2021, or the Merger Agreement, to acquire Lowell Therapeutics, Inc., or Lowell, a privately held company (see Note 4. “Asset Acquisition” below). As a result of the Merger Agreement, the Company acquired Niyad™, a regional anticoagulant for the dialysis circuit during continuous renal replacement therapy for acute kidney injury patients in the hospital, that the Company plans to study under an investigational device exemption, or IDE, and which has received Breakthrough Device Designation status from the FDA. While not approved for commercial use in the U.S., the active drug component of Niyad, nafamostat, has been approved in Japan and South Korea as a regional anticoagulant for the dialysis circuit, disseminated intravascular coagulation, and acute pancreatitis. Niyad is a lyophilized formulation of nafamostat, a broad-spectrum, synthetic serine protease inhibitor, with anticoagulant, anti-inflammatory, and potential anti-viral activities. The second intended indication for Niyad is as a regional anticoagulant for the dialysis circuit for chronic kidney disease patients undergoing intermittent hemodialysis in dialysis centers. In addition, the Company acquired LTX-608, a proprietary nafamostat formulation for direct IV infusion that it intends to develop for the treatment of acute respiratory distress syndrome, or ARDS, and disseminated intravascular coagulation, or DIC.

Termination of Grünenthal Agreements

On December 16, 2013, AcelRx and Grünenthal entered into a Collaboration and License Agreement, or the License Agreement, which was amended effective July 17, 2015 and September 20, 2016, or the Amended License Agreement, which granted Grünenthal rights to commercialize the Zalviso PCA system, or the Product, in the 28 European Union, or EU, member states, at the time of the agreement, plus Switzerland, Liechtenstein, Iceland, Norway and Australia (collectively, the Zalviso Territory) for human use in pain treatment within, or dispensed by, hospitals, hospices, nursing homes and other medically supervised settings, (collectively, the Field). In September 2015, the EC granted marketing approval for the marketing authorization application, or MAA, previously submitted to the EMA, for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. On December 16, 2013, AcelRx and Grünenthal entered into a Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements. Under the MSA, the Company exclusively manufactured and supplied the Product to Grünenthal for the Field in the Zalviso Territory. On July 22, 2015, the Company and Grünenthal amended the MSA, or the Amended MSA, effective as of July 17, 2015. The Amended MSA and the Amended License Agreement are referred to as the Grünenthal Agreements.

On May 18, 2020, the Company received a notice from Grünenthal that it had exercised its right to terminate the Grünenthal Agreements, effective November 13, 2020. The terms of the Grünenthal Agreements were extended to May 12, 2021 to enable Grünenthal to sell down its Zalviso inventory, a right it had under the Grünenthal Agreements. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on May 12, 2021. In July 2022, the European Marketing Authorization for Zalviso was withdrawn.

Termination of Royalty Monetization

On September 18, 2015, the Company sold the majority of the royalty rights and certain commercial sales milestones it was entitled to receive under the Amended License Agreement with Grünenthal to PDL BioPharma, Inc., or PDL, in a transaction referred to as the Royalty Monetization. On August 31, 2020, PDL announced it sold its royalty interest for Zalviso to SWK Funding, LLC, or SWK. On May 31, 2022, the Company entered into the Termination Agreement with SWK to fully terminate the Royalty Monetization for which the Company paid cash consideration of $0.1 million. Neither PDL nor SWK retains any further interest in the Royalty Monetization. Accordingly, effective May 31, 2022, the Royalty Monetization is no longer reflected on the Company’s financial statements or other records as a sale of assets to PDL or SWK and all security interests and other liens of every type held by the parties to the Royalty Monetization have been terminated and automatically released without further action by any party. The $84.1 million gain on extinguishment of the liability related to the sale of future royalties is recognized in the Condensed Consolidated Statements of Operations as Other Income.

Liquidity and Going Concern

The Condensed Consolidated Financial Statements for the three and six months ended June 30, 2022 were prepared on the basis of a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. The termination of the Royalty Monetization resulted in net income for the three and six months ended June 30, 2022; however, before this, the Company had incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur operating losses and negative cash flows in the future. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Considering the Company’s current cash resources and its current and expected levels of operating expenses for the next twelve months, management expects to need additional capital to fund its planned operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the United States Securities and Exchange Commission, or SEC. Management may seek to raise such additional capital through public or private equity offerings, including under the Controlled Equity Offering^SM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co., or Cantor, debt securities, monetize or securitize certain assets, refinance its loan agreement, enter into product development, license or distribution agreements with third parties, or divest DSUVIA in the United States, DZUVEO in Europe, or any of the Company’s product candidates. While management believes its plans to raise additional funds will alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, these plans are not entirely within the Company’s control and cannot be assessed as being probable of occurring. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available, the Company may be required to further reduce its workforce, reduce the scope of, or cease, the commercial launch of DSUVIA, or the development of its product candidates in advance of the date on which the Company’s cash resources are exhausted to ensure that the Company has sufficient capital to meet its obligations and continue on a path designed to preserve stockholder value. In addition, if additional funds are raised through collaborations, strategic alliances or licensing arrangements with third parties, the Company may have to relinquish rights to its technologies, future revenue streams or product candidates, or to grant licenses on terms that may not be favorable to the Company.

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the United States Securities and Exchange Commission, or SEC. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

Operating results for the three and six months ended June 30, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, 2022, or any future period. The Condensed Consolidated Balance Sheet as of December 31, 2021, was derived from the Company’s consolidated audited financial statements as of December 31, 2021, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 10, 2022. These consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which includes a broader discussion of the Company’s business and the risks inherent therein.

Reclassification, Comparability Adjustment [Policy Text Block]

Reclassifications

Certain prior year amounts in the Consolidated Financial Statements have been reclassified to conform to the current year's presentation. In particular, the restricted cash classified as “Cash and cash equivalents” has been reclassified to “Restricted cash, net of current portion” in the Condensed Consolidated Balance Sheets as of December 31, 2021 and in the Condensed Consolidated Statement of Cash Flows as of December 31, 2021, June 30, 2021 and December 31, 2020. See “—Cash, Cash Equivalents and Restricted Cash” below.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with an original maturity (at date of purchase) of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks.

On May 30, 2019, the Company entered into the Loan Agreement with Oxford Finance LLC, or Oxford, as the Lender. The Loan Agreement requires that the Company always maintain unrestricted cash of not less than $5.0 million in accounts subject to control agreements in favor of the Lender, tested monthly as of the last day of the month. As of June 30, 2022, the Company has classified these unrestricted funds as restricted cash on the Condensed Consolidated Balance Sheets.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets that sum to the total of the same such amounts in the Condensed Consolidated Statement of Cash Flows:

	Balance as of
	June 30, 2022		December 31, 2021
Cash and cash equivalents	$	15,165	$	7,663
Restricted cash		5,000		—
Restricted cash, net of current portion		—		5,000
Total cash, cash equivalents, and restricted cash	$	20,165	$	12,663

	Balance as of
	June 30, 2021		December 31, 2020
Cash and cash equivalents	$	21,327	$	22,274
Restricted cash, net of current portion		5,000		5,000
Total cash, cash equivalents, and restricted cash	$	26,327	$	27,274

Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]

Restructuring Costs

The Company's restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period.

In May 2022, the Company initiated a reorganization that eliminated approximately 40% of its employees, primarily within the commercial organization. For the three months ended June 30, 2022, the Company incurred approximately $0.5 million in employee termination benefits related to this restructuring, all which has been paid at June 30, 2022. This headcount reduction was completed in the second quarter of 2022. No additional expenses are anticipated in connection with this cost reduction plan.

Business Combinations Policy [Policy Text Block]

Acquisitions

The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.

Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.

For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development (“IPR&D”) asset, the IPR&D asset is only capitalized if it has an alternative future use other than in a particular research and development project. For an IPR&D asset to have an alternative future use: (a) the Company must reasonably expect that it will use the asset acquired in the alternative manner and anticipate economic benefit from that alternative use, and (b) the Company’s use of the asset acquired is not contingent on further development of the asset subsequent to the acquisition date (that is, the asset can be used in the alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts allocated to IPR&D that have no alternative use are expensed. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-13, “Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments,” or ASU 2016-13. ASU 2016-13 replaces the incurred loss impairment model in current GAAP with a model that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to determine credit loss estimates. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early adoption allowed beginning January 1, 2020. In May 2019, the FASB issued ASU 2019-05, “Financial Instruments – Credit Losses,” or ASU 2019-05, to allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost upon adoption of the new credit losses standard. The new effective dates and transition align with those of ASU 2016-13. Management is currently assessing the date of adoption and the impact ASU 2016-13 and ASU 2019-05 will have on the Company, but it does not anticipate adoption of these new standards to have a material impact on the Company’s financial position, results of operations or cash flows.

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,” which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. In January 2021, the FASB issued ASU 2021-01, “Reference Rate Reform (Topic 848),” to expand and clarify the scope of Topic 848 to include derivative instruments on discounting transactions. The amendments in this ASU are effective in the same timeframe as ASU 2020-04. The Company is currently evaluating the impact this guidance will have on its Consolidated Financial Statements.

Note 13 - Net Income (Loss) Per Share of Common Stock

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Text Block]

13. Net Income (Loss) per Share of Common Stock

The Company’s basic net income (loss) per share of common stock is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. The diluted net income (loss) per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, RSUs, and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive.

The following table sets forth the computation of the Company’s basic and diluted net income (loss) per share of common stock during the three and six months ended June 30, 2022 and 2021 (in thousands, except for share and per share amounts):

	Three Months Ended June 30,					Six Months Ended June 30,
	2022		2021			2022		2021
	(in thousands, except share and per share amounts)
Numerator:
Net income (loss)	$	70,663	$	(9,851	)	$	61,989	$	(18,807	)
Denominator:
Weighted average shares outstanding — basic		147,139,032		119,120,040			146,385,577		116,204,492
Dilutive effect of RSUs		70,033		—			34,860		—
Weighted average shares outstanding — diluted		147,209,065		119,120,040			146,420,437		116,204,492

Net income (loss) per share — basic	$	0.48	$	(0.08	)	$	0.42	$	(0.16	)
Net income (loss) per share — diluted	$	0.48	$	(0.08	)	$	0.42	$	(0.16	)

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net income (loss) per share of common stock for the periods presented because including them would have been antidilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
RSUs, stock options and ESPP to purchase common stock		16,520,200		16,907,412		16,463,459		16,907,412
Common stock warrants		17,676,679		176,679		17,676,679		176,679

In addition, the shares held back and contingently issuable in connection with the Lowell Merger, as described in Note 4. above, have also been excluded from the computation of diluted net income (loss) per share of common stock for the periods presented because the contingencies for issuance of these shares have not been met.

Note 8 - Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating lease costs	$ 343	$ 440	$ 686	$ 780
Gain on derecognition of operating lease	0	0	0	(522)
Sublease income	0	(50)	0	(199)
Loss on termination of sublease	0	331	0	331
Net lease costs	$ 343	$ 721	$ 686	$ 390
Weighted-average remaining lease term – operating leases (years) (Year)	4 years 6 months 25 days	5 years 4 months 28 days	4 years 6 months 25 days	5 years 4 months 28 days
Weighted-average remaining discount rate – operating leases	12.80%	12.80%	12.80%	12.80%

Note 8 - Leases - Maturities of Lease Liabilities (Details) - USD ($)
$ in Thousands

Jun. 30, 2022

Dec. 31, 2021

^[1]

2022 (remaining six months)

$ 921

1,344

1,040

1,040

1,040

415

Total future minimum lease payments

5,800

Less imputed interest

(1,299)

Total

4,501

Operating lease liabilities

4,501

Operating lease liabilities, current portion

(1,142)

$ (1,068)

Operating lease liabilities, net of current portion

$ 3,359

$ 3,750

[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 10 - Commitments and Contingencies (Details Textual)	Jul. 06, 2021	Jun. 08, 2021
Purported Shareholder v. Company - Violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 [Member]
Loss Contingency, Number of Defendants		2
Purported Shareholder v. Company - Alleged Misstatements as the Shareholder [Member]
Loss Contingency, Number of Defendants	10

Note 1 - Organization and Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2022

Basis of Presentation and Significant Accounting Policies [Text Block]

1. Organization and Summary of Significant Accounting Policies

The Company

AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on July 13, 2005 as SuRx, Inc. The Company subsequently changed its name to AcelRx Pharmaceuticals, Inc. The Company’s operations are based in Hayward, California.

AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA®(known as DZUVEO® in Europe) and Zalviso® areboth focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, exclusively for use in medically supervised settings. On November 2, 2018, the U.S. Food and Drug Administration, or FDA, approved DSUVIA for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The commercial launch of DSUVIA in the United States occurred in the first quarter of 2019. In June 2018, the European Commission, or EC, granted marketing approval of DZUVEO for the management of acute moderate to severe pain in adults in medically monitored settings. AcelRx is further developing a distribution capability and commercial organization to continue to market and sell DSUVIA in the United States. In geographies where AcelRx decides not to commercialize products by itself, the Company may seek to out-license commercialization rights. The Company currently intends to commercialize and promote DSUVIA/DZUVEO outside the United States with one or more strategic partners, and, in July 2021, entered into a License and Commercialization Agreement with Laboratoire Aguettant, or Aguettant, for Aguettant to commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom, or the DZUVEO Agreement. Zalviso was approved in Europe and was commercialized by Grünenthal GmbH, or Grünenthal, through May 12, 2021 (see Termination of Grünenthal Agreements below). In July 2022, the European Marketing Authorization for Zalviso was withdrawn. In July 2021, the Company also entered into a separate License and Commercialization Agreement with Aguettant pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing 10 ml of a solution of 50 mcg/ml phenylephrine hydrochloride for injection. On January 7, 2022, the Company closed the definitive merger agreement dated as of November 14, 2021, or the Merger Agreement, to acquire Lowell Therapeutics, Inc., or Lowell, a privately held company (see Note 4. “Asset Acquisition” below). As a result of the Merger Agreement, the Company acquired Niyad™, a regional anticoagulant for the dialysis circuit during continuous renal replacement therapy for acute kidney injury patients in the hospital, that the Company plans to study under an investigational device exemption, or IDE, and which has received Breakthrough Device Designation status from the FDA. While not approved for commercial use in the U.S., the active drug component of Niyad, nafamostat, has been approved in Japan and South Korea as a regional anticoagulant for the dialysis circuit, disseminated intravascular coagulation, and acute pancreatitis. Niyad is a lyophilized formulation of nafamostat, a broad-spectrum, synthetic serine protease inhibitor, with anticoagulant, anti-inflammatory, and potential anti-viral activities. The second intended indication for Niyad is as a regional anticoagulant for the dialysis circuit for chronic kidney disease patients undergoing intermittent hemodialysis in dialysis centers. In addition, the Company acquired LTX-608, a proprietary nafamostat formulation for direct IV infusion that it intends to develop for the treatment of acute respiratory distress syndrome, or ARDS, and disseminated intravascular coagulation, or DIC.

Termination of Grünenthal Agreements

On December 16, 2013, AcelRx and Grünenthal entered into a Collaboration and License Agreement, or the License Agreement, which was amended effective July 17, 2015 and September 20, 2016, or the Amended License Agreement, which granted Grünenthal rights to commercialize the Zalviso PCA system, or the Product, in the 28 European Union, or EU, member states, at the time of the agreement, plus Switzerland, Liechtenstein, Iceland, Norway and Australia (collectively, the Zalviso Territory) for human use in pain treatment within, or dispensed by, hospitals, hospices, nursing homes and other medically supervised settings, (collectively, the Field). In September 2015, the EC granted marketing approval for the marketing authorization application, or MAA, previously submitted to the EMA, for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. On December 16, 2013, AcelRx and Grünenthal entered into a Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements. Under the MSA, the Company exclusively manufactured and supplied the Product to Grünenthal for the Field in the Zalviso Territory. On July 22, 2015, the Company and Grünenthal amended the MSA, or the Amended MSA, effective as of July 17, 2015. The Amended MSA and the Amended License Agreement are referred to as the Grünenthal Agreements.

On May 18, 2020, the Company received a notice from Grünenthal that it had exercised its right to terminate the Grünenthal Agreements, effective November 13, 2020. The terms of the Grünenthal Agreements were extended to May 12, 2021 to enable Grünenthal to sell down its Zalviso inventory, a right it had under the Grünenthal Agreements. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on May 12, 2021. In July 2022, the European Marketing Authorization for Zalviso was withdrawn.

Termination of Royalty Monetization

On September 18, 2015, the Company sold the majority of the royalty rights and certain commercial sales milestones it was entitled to receive under the Amended License Agreement with Grünenthal to PDL BioPharma, Inc., or PDL, in a transaction referred to as the Royalty Monetization. On August 31, 2020, PDL announced it sold its royalty interest for Zalviso to SWK Funding, LLC, or SWK. On May 31, 2022, the Company entered into the Termination Agreement with SWK to fully terminate the Royalty Monetization for which the Company paid cash consideration of $0.1 million. Neither PDL nor SWK retains any further interest in the Royalty Monetization. Accordingly, effective May 31, 2022, the Royalty Monetization is no longer reflected on the Company’s financial statements or other records as a sale of assets to PDL or SWK and all security interests and other liens of every type held by the parties to the Royalty Monetization have been terminated and automatically released without further action by any party. The $84.1 million gain on extinguishment of the liability related to the sale of future royalties is recognized in the Condensed Consolidated Statements of Operations as Other Income.

Liquidity and Going Concern

The Condensed Consolidated Financial Statements for the three and six months ended June 30, 2022 were prepared on the basis of a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. The termination of the Royalty Monetization resulted in net income for the three and six months ended June 30, 2022; however, before this, the Company had incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur operating losses and negative cash flows in the future. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Considering the Company’s current cash resources and its current and expected levels of operating expenses for the next twelve months, management expects to need additional capital to fund its planned operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the United States Securities and Exchange Commission, or SEC. Management may seek to raise such additional capital through public or private equity offerings, including under the Controlled Equity Offering^SM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co., or Cantor, debt securities, monetize or securitize certain assets, refinance its loan agreement, enter into product development, license or distribution agreements with third parties, or divest DSUVIA in the United States, DZUVEO in Europe, or any of the Company’s product candidates. While management believes its plans to raise additional funds will alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, these plans are not entirely within the Company’s control and cannot be assessed as being probable of occurring. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available, the Company may be required to further reduce its workforce, reduce the scope of, or cease, the commercial launch of DSUVIA, or the development of its product candidates in advance of the date on which the Company’s cash resources are exhausted to ensure that the Company has sufficient capital to meet its obligations and continue on a path designed to preserve stockholder value. In addition, if additional funds are raised through collaborations, strategic alliances or licensing arrangements with third parties, the Company may have to relinquish rights to its technologies, future revenue streams or product candidates, or to grant licenses on terms that may not be favorable to the Company.

Principles of Consolidation

The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the United States Securities and Exchange Commission, or SEC. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

Operating results for the three and six months ended June 30, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, 2022, or any future period. The Condensed Consolidated Balance Sheet as of December 31, 2021, was derived from the Company’s consolidated audited financial statements as of December 31, 2021, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 10, 2022. These consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which includes a broader discussion of the Company’s business and the risks inherent therein.

Reclassifications

Certain prior year amounts in the Consolidated Financial Statements have been reclassified to conform to the current year's presentation. In particular, the restricted cash classified as “Cash and cash equivalents” has been reclassified to “Restricted cash, net of current portion” in the Condensed Consolidated Balance Sheets as of December 31, 2021 and in the Condensed Consolidated Statement of Cash Flows as of December 31, 2021, June 30, 2021 and December 31, 2020. See “—Cash, Cash Equivalents and Restricted Cash” below.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with an original maturity (at date of purchase) of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks.

On May 30, 2019, the Company entered into the Loan Agreement with Oxford Finance LLC, or Oxford, as the Lender. The Loan Agreement requires that the Company always maintain unrestricted cash of not less than $5.0 million in accounts subject to control agreements in favor of the Lender, tested monthly as of the last day of the month. As of June 30, 2022, the Company has classified these unrestricted funds as restricted cash on the Condensed Consolidated Balance Sheets.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets that sum to the total of the same such amounts in the Condensed Consolidated Statement of Cash Flows:

Balance as of

June 30, 2022

December 31, 2021

Cash and cash equivalents
$ 15,165 $ 7,663

Restricted cash
5,000 —

Restricted cash, net of current portion
— 5,000

Total cash, cash equivalents, and restricted cash
$ 20,165 $ 12,663

Balance as of

June 30, 2021

December 31, 2020

Cash and cash equivalents
$ 21,327 $ 22,274

Restricted cash, net of current portion
5,000 5,000

Total cash, cash equivalents, and restricted cash
$ 26,327 $ 27,274

Restructuring Costs

The Company's restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period.

In May 2022, the Company initiated a reorganization that eliminated approximately 40% of its employees, primarily within the commercial organization. For the three months ended June 30, 2022, the Company incurred approximately $0.5 million in employee termination benefits related to this restructuring, all which has been paid at June 30, 2022. This headcount reduction was completed in the second quarter of 2022. No additional expenses are anticipated in connection with this cost reduction plan.

Significant Accounting Policies

The Company’s significant accounting policies are detailed in its Annual Report on Form 10-K for the year ended December 31, 2021. There have been no significant changes to the Company’s significant accounting policies during the six months ended June 30, 2022, from those previously disclosed in its 2021 Annual Report on Form 10-K, except as follows:

Acquisitions

The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.

Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.

For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development (“IPR&D”) asset, the IPR&D asset is only capitalized if it has an alternative future use other than in a particular research and development project. For an IPR&D asset to have an alternative future use: (a) the Company must reasonably expect that it will use the asset acquired in the alternative manner and anticipate economic benefit from that alternative use, and (b) the Company’s use of the asset acquired is not contingent on further development of the asset subsequent to the acquisition date (that is, the asset can be used in the alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts allocated to IPR&D that have no alternative use are expensed. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.

Recently Issued Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-13, “Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments,” or ASU 2016-13. ASU 2016-13 replaces the incurred loss impairment model in current GAAP with a model that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to determine credit loss estimates. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early adoption allowed beginning January 1, 2020. In May 2019, the FASB issued ASU 2019-05, “Financial Instruments – Credit Losses,” or ASU 2019-05, to allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost upon adoption of the new credit losses standard. The new effective dates and transition align with those of ASU 2016-13. Management is currently assessing the date of adoption and the impact ASU 2016-13 and ASU 2019-05 will have on the Company, but it does not anticipate adoption of these new standards to have a material impact on the Company’s financial position, results of operations or cash flows.

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,” which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. In January 2021, the FASB issued ASU 2021-01, “Reference Rate Reform (Topic 848),” to expand and clarify the scope of Topic 848 to include derivative instruments on discounting transactions. The amendments in this ASU are effective in the same timeframe as ASU 2020-04. The Company is currently evaluating the impact this guidance will have on its Consolidated Financial Statements.

Note 6 - Revenue From Contracts With Customers

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Text Block]

6. Revenue from Contracts with Customers

The following table summarizes revenue from contracts with customers for the three and six months ended June 30, 2022 and 2021 into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors (in thousands):

	Three months ended June 30, 2022		Six months ended June 30, 2022
Product sales:
DSUVIA	$	444	$	886
DZUVEO¹		126		126
Total product sales	$	570	$	1,012

¹ Represents sales to our partner in Europe for their expected product launch in the third quarter of 2022.

	Three months ended June 30, 2021		Six months ended June 30, 2021
Product sales:
DSUVIA	$	392	$	573
Zalviso		—		270
Total product sales		392		843

Contract and collaboration revenue:
Non-cash royalty revenue related to Royalty Monetization (Note 9)		38		83
Royalty revenue		13		28
Total revenues from contract and other collaboration		51		111
Total revenue	$	443	$	954

For additional details on the Company’s accounting policy regarding revenue recognition, refer to Note 1 “Organization and Summary of Significant Accounting Policies - Revenue from Contracts with Customers” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Product Sales

The Company’s commercial launch of DSUVIA in the United States occurred in the first quarter of 2019. Zalviso was sold in Europe by the Company’s collaboration partner, Grünenthal, through May 12, 2021, at which time, due to the termination of the Grünenthal Agreements, the rights to market and sell Zalviso in Europe reverted back to the Company. In July 2022, the European Marketing Authorization for Zalviso was withdrawn. DZUVEO sales in Europe by the Company’s collaboration partner, Aguettant, have not commenced as of June 30, 2022.

Contract and Other Collaboration

Contract and other collaboration revenue includes revenue under the Grünenthal Agreements related to research and development services, non-cash royalty revenue related to the Royalty Monetization and royalty revenue for sales of Zalviso in Europe and license revenue recognized under the DZUVEO Agreement. For the three and six months ended June 30, 2022, the Company did not record any contract and other collaboration revenue.

Contract Liabilities

A contract liability of $1.2 million was recorded on the Condensed Consolidated Balance Sheets as deferred revenue as of June 30, 2022, $0.1 million of which represented the current portion, for the portion of the upfront fee received under the DZUVEO Agreement allocated to the material right for discounted price on future optional product supply which has not yet been satisfied. The material right contract liability will be recognized over the period the discount on future product supply is made available.

The following table presents changes in the Company’s contract liability for the six months ended June 30, 2022 and 2021 (in thousands):

Balance at January 1, 2022	$	1,237
Deductions for performance obligations satisfied:
In current period		(29	)
Balance at June 30, 2022	$	1,208

Balance at January 1, 2021	$	49
Deductions for performance obligations satisfied:
In current period		(49	)
Balance at June 30, 2021	$	—

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Note 4 - Asset Acquisition

6 Months Ended

Jun. 30, 2022

Business Combination Disclosure [Text Block]

4. Asset Acquisition

On January 7, 2022, the Company closed the Merger Agreement with Lowell. Under the terms of the agreement, the Company acquired the product nafamostat, and the associated patents and historical know-how. The acquisition was valued at approximately $32.5 million plus cash acquired of $3.5 million and certain other adjustments. Pursuant to the terms of the Merger Agreement, all options to purchase capital stock and all shares of Lowell capital stock issued and outstanding immediately before the effective time of the merger were cancelled in exchange for the right to receive (i) 9,009,538 shares of AcelRx common stock issued at a five day daily volume weighted average price of $0.57284 per share as of January 7, 2022, or the Acquisition Date, valued at $5.2 million on closing, (ii) cash in the amount of $3.5 million, (iii) 1,396,526 shares of AcelRx common stock to be held back to satisfy any potential indemnification and other obligations of Lowell and its securityholders valued at $0.8 million, (iv) $0.5 million cash and stock paid for sellers’ transaction costs and (v) up to $26.0 million of contingent consideration payable in cash or stock at AcelRx's option, upon the achievement of regulatory and sales-based milestones.

The shares issued pursuant to the Merger Agreement were issued in private placements pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, or the Securities Act, including Rule 506 of Regulation D promulgated under the Securities Act, or Regulation D, without general solicitation as a transaction not involving any public offering.

The Merger Agreement has been accounted for as an asset acquisition of a single IPR&D asset that has an alternative future use. The initial measurement of the asset purchased of $8.8 million was based on the purchase cost of $12.4 million including (i) $6.0 million common stock fair value on the closing date (issued and held back on the acquisition date), (ii) $0.5 million seller’s costs paid by the Company, (iii) $3.5 million cash and (iv) approximately $2.5 million of transaction costs less purchase price allocated to cash acquired of $3.5 million. Due to the nature of regulatory and sales-based milestones, the contingent consideration of up to $26.0 million was not included in the initial cost of the assets purchased as they are contingent upon events that are outside the Company’s control, such as regulatory approvals and issuance of patents, and are not considered probable until notification is received. However, upon achievement or anticipated achievement of each milestone, the Company shall recognize the related, appropriate payment as an additional cost of the acquired IPR&D asset. As of June 30, 2022, none of the contingent events has occurred.

The following table summarizes the total consideration for the acquisition and the value of the IPR&D asset acquired (in thousands):

Consideration
Cash	$	3,536
Issuance of common stock to Lowell security holders in connection with asset acquisition		5,161
Issuance of common stock to settle Lowell’s transaction costs in connection with asset acquisition		350
Liability for issuance of 1,396,526 hold back shares to Lowell securityholders⁽¹⁾		800
Transaction costs		2,521
Total consideration	$	12,368

IPR&D Asset Acquired
Purchase price	$	12,368
Cash acquired		(3,549	)
Total IPR&D asset acquired⁽²⁾	$	8,819

⁽¹⁾ Recorded as Other long-term liabilities in the Condensed Consolidated Balance Sheets.

⁽²⁾Recorded as In-process research and development asset in the Condensed Consolidated Balance Sheets.

The IPR&D asset will be treated initially as an indefinite-lived asset, and as a long-lived asset, it will be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If the IPR&D asset achieves regulatory approval and the asset life is determined to be finite, the asset’s useful life will be estimated, and the asset will be amortized over its remaining useful life. No impairment losses were recorded on the IPR&D asset during the three and six months ended June 30, 2022.

Note 11 - Stockholders' Equity (Details Textual) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
	May 09, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Proceeds from Issuance of Common Stock				$ 0	$ 36,360
ATM Agreement [Member]
Aggregate Offering Price, Maximum	$ 80,000			$ 36,100
Stock Issued During Period, Shares, New Issues (in shares)		0	3,000	0	3,000
Proceeds from Issuance of Common Stock			$ 7,500		$ 7,500

Note 12 - Stock-based Compensation

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Text Block]

12. Stock-Based Compensation

The Company recorded total stock-based compensation expense for stock options, restricted stock units, or RSUs, and the Amended and Restated 2011 Employee Stock Purchase Plan, or the Amended ESPP, as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Cost of goods sold	$	16	$	21	$	35	$	43
Research and development		153		200		327		381
Selling, general and administrative		584		951		1,174		1,837
Total	$	753	$	1,172	$	1,536	$	2,261

The following table summarizes restricted stock unit activity under the Company’s equity incentive plans:

				Weighted
	Number of			*Average*
	*Restricted*			Grant Date
	Stock Units			Fair Value
Restricted stock units outstanding, January 1, 2022		1,774,376		$	1.71
Granted		1,061,826			0.40
Vested		(880,315	)		1.78
Forfeited		(313,288	)		1.29
Restricted stock units outstanding, June 30, 2022		1,642,599		$	0.91

Upon vesting, certain of the Company’s RSUs may be settled on a net-exercise basis to cover any required withholding tax with the remaining amount converted into an equivalent number of shares of common stock. There were 0 and 141,966 shares of common stock underlying vested RSUs that were withheld during the three and six months ended June 30, 2022, respectively, based on the value of the RSUs as determined by the Company’s closing stock price on the applicable vesting date.

The following table summarizes stock option activity under the Company’s equity incentive plans:

	Number of Stock Options Outstanding			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
								(in thousands)
January 1, 2022		14,284,050		$	2.99
Granted		2,123,650			0.40
Forfeited		(552,745	)		1.37
Expired		(812,693	)		3.31
Exercised		—			—

June 30, 2022		15,042,262		$	2.67		5.8	$	—

Vested and exercisable options—June 30, 2022		10,473,947		$	3.31		4.5	$	—
Vested and expected to vest—June 30, 2022		15,042,262		$	2.67		5.8	$	—

The per-share weighted average grant date fair value of the options granted for the six months ended June 30, 2022 was estimated at $0.30 per share on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions:

	Six months ended June 30, 2022
Expected term (in years)		6.3
Risk-free interest rate	1.6%	-	2.2%
Expected volatility		88%
Expected dividend rate		0%

As of June 30, 2022, there were 6,352,183 shares available for grant under the Company’s equity incentive plans and 4,302,929 shares available for grant under the Amended ESPP.

Note 14 - Subsequent Event (Details Textual) - Subsequent Event [Member]	Aug. 03, 2022 USD ($) $ / shares shares
Warrants Issued with Securities Purchase Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares	1,623,008
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 0.2033
Securities Purchase Agreement [Member]
Proceeds from Issuance or Sale of Equity, Total \| $	$ 300,000
Securities Purchase Agreement [Member] \| Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares	3,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.001

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended	6 Months Ended		78 Months Ended
	May 31, 2022	May 31, 2022	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022	May 30, 2019
Consideration Paid for Termination of Royalty Monetization	$ 100			$ 100		$ 100
Gain on Termination of Liability Related to Sale of Future Royalties	$ 84,100			$ 84,152	$ (0)
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent		40.00%
Severance Costs			$ 500
Loan Agreement with Oxford Finance LLC [Member]
Debt Instrument, Covenant, Minimum Required Unrestircted Cash							$ 5,000

Note 6 - Revenue From Contracts With Customers - Contract Liability (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Balance	$ 1,237	$ 49
In current period	(29)	(49)
Balance	$ 1,208	$ 0

Note 13 - Net Income (Loss) Per Share of Common Stock (Tables)

6 Months Ended

Jun. 30, 2022

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended June 30,					Six Months Ended June 30,
	2022		2021			2022		2021
	(in thousands, except share and per share amounts)
Numerator:
Net income (loss)	$	70,663	$	(9,851	)	$	61,989	$	(18,807	)
Denominator:
Weighted average shares outstanding — basic		147,139,032		119,120,040			146,385,577		116,204,492
Dilutive effect of RSUs		70,033		—			34,860		—
Weighted average shares outstanding — diluted		147,209,065		119,120,040			146,420,437		116,204,492

Net income (loss) per share — basic	$	0.48	$	(0.08	)	$	0.42	$	(0.16	)
Net income (loss) per share — diluted	$	0.48	$	(0.08	)	$	0.42	$	(0.16	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
RSUs, stock options and ESPP to purchase common stock		16,520,200		16,907,412		16,463,459		16,907,412
Common stock warrants		17,676,679		176,679		17,676,679		176,679

Note 5 - Property and Equipment, Net - Components of Property and Equipment (Details) - USD ($)
$ in Thousands

Jun. 30, 2022

Dec. 31, 2021

Less accumulated depreciation and amortization

$ 22,368

$ 26,714

(11,293)

(10,786)

Property and equipment, net

11,075

15,928

^[1]

Laboratory Equipment [Member]

Leasehold Improvements [Member]

4,406

Computer Equipment and Software [Member]

5,838

Construction in Progress [Member]

1,589

9,459

13,805

Tooling [Member]

Furniture and Fixtures [Member]

826

$ 250

[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Revenue	$ 570	$ 443	$ 1,012	$ 954
Operating costs and expenses:
Cost of goods sold	876	1,040	1,660	2,080
Research and development	1,544	724	2,859	1,693
Selling, general and administrative	6,822	8,694	14,160	16,338
Impairment of property and equipment	4,901	0	4,901	0
Total operating costs and expenses	14,143	10,458	23,580	20,111
Income (loss) from operations	(13,573)	(10,015)	(22,568)	(19,157)
Other income:
Interest expense	(327)	(614)	(717)	(1,286)
Interest income and other (expense) income, net	51	(16)	89	60
Non-cash interest income on liability related to the sale of future royalties	463	799	1,136	1,581
Gain on extinguishment of liability related to the sale of future royalties	84,052	0	84,052	0
Total other income	84,239	169	84,560	355
Net income (loss) before income taxes	70,666	(9,846)	61,992	(18,802)
Provision for income taxes	(3)	(5)	(3)	(5)
Net income (loss)	$ 70,663	$ (9,851)	$ 61,989	$ (18,807)
Net income (loss) per share of common stock, basic (in dollars per share)	$ 0.48	$ (0.08)	$ 0.42	$ (0.16)
Shares used in computing net income (loss) per share of common stock, basic – See Note 13 (in shares)	147,139,032	119,120,040	146,385,577	116,204,492
Net income (loss) per share of common stock, diluted (in dollars per share)	$ 0.48	$ (0.08)	$ 0.42	$ (0.16)
Shares used in computing net income (loss) per share of common stock, diluted – See Note 13 (in shares)	147,209,065	119,120,040	146,420,437	116,204,492
Product [Member]
Revenue:
Revenue	$ 570	$ 392	$ 1,012	$ 843
Contract and Other Collaboration [Member]
Revenue:
Revenue	$ 0	$ 51	$ 0	$ 111

Note 8 - Leases (Tables)

6 Months Ended

Jun. 30, 2022

Lease, Cost [Table Text Block]

	Three Months Ended June 30,					Six Months Ended June 30,
	2022		2021			2022		2021
Operating lease costs	$	343	$	440		$	686	$	780
Gain on derecognition of operating lease		—		—			—		(522	)
Sublease income		—		(50	)		—		(199	)
Loss on termination of sublease		—		331			—		331
Net lease costs	$	343	$	721		$	686	$	390

	June 30, 2022			June 30, 2021
Weighted-average remaining lease term – operating leases (years)	4.57			5.41
Weighted-average remaining discount rate – operating leases		12.8	%		12.8	%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Year:
2022 (remaining six months)	$	921
2023		1,344
2024		1,040
2025		1,040
2026		1,040
Thereafter		415
Total future minimum lease payments		5,800
Less imputed interest		(1,299	)
Total	$	4,501

Reported as:
Operating lease liabilities	$	4,501
Operating lease liabilities, current portion		(1,142	)
Operating lease liabilities, net of current portion	$	3,359

Note 6 - Revenue From Contracts With Customers (Tables)

6 Months Ended

Jun. 30, 2022

Disaggregation of Revenue [Table Text Block]

	Three months ended June 30, 2022		Six months ended June 30, 2022
Product sales:
DSUVIA	$	444	$	886
DZUVEO¹		126		126
Total product sales	$	570	$	1,012

	Three months ended June 30, 2021		Six months ended June 30, 2021
Product sales:
DSUVIA	$	392	$	573
Zalviso		—		270
Total product sales		392		843

Contract and collaboration revenue:
Non-cash royalty revenue related to Royalty Monetization (Note 9)		38		83
Royalty revenue		13		28
Total revenues from contract and other collaboration		51		111
Total revenue	$	443	$	954

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

Balance at January 1, 2022	$	1,237
Deductions for performance obligations satisfied:
In current period		(29	)
Balance at June 30, 2022	$	1,208

Balance at January 1, 2021	$	49
Deductions for performance obligations satisfied:
In current period		(49	)
Balance at June 30, 2021	$	—

Note 1 - Organization and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2022

Schedule of Cash and Cash Equivalents [Table Text Block]

	Balance as of
	June 30, 2022		December 31, 2021
Cash and cash equivalents	$	15,165	$	7,663
Restricted cash		5,000		—
Restricted cash, net of current portion		—		5,000
Total cash, cash equivalents, and restricted cash	$	20,165	$	12,663

	Balance as of
	June 30, 2021		December 31, 2020
Cash and cash equivalents	$	21,327	$	22,274
Restricted cash, net of current portion		5,000		5,000
Total cash, cash equivalents, and restricted cash	$	26,327	$	27,274

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares

Jun. 30, 2022

Dec. 31, 2021

^[1]

Common stock, par value (in dollars per share)

$ 0.001

Common stock, shares authorized (in shares)

200,000,000

Common stock, shares issued (in shares)

147,331,963

136,819,647

Common stock, shares outstanding (in shares)

147,331,963

136,819,647

[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 4 - Asset Acquisition (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

Jan. 07, 2022

Jun. 30, 2022

In Process Research and Development [Member]

Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)

$ 0

Lowell Therapeutics [Member]

Business Combination, Consideration Transferred, Net of Cash Acquired

$ 32,500

Cash Acquired from Acquisition

3,549

Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Cash

$ 3,500

Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares)

1,396,526

Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Value

^[1]

$ 800

Business Combination, Cash and Stock Paid for Transaction Costs

500

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total

^[2]

8,819

Business Combination, Consideration Transferred, Total

12,368

Business Combination, Consideration Transferred, Equity Interests Issued and Issuable

6,000

Business Combination, Acquisition Related Costs

500

Payments to Acquire Businesses, Gross

3,536

Business Acquisition, Transaction Costs

2,521

Lowell Therapeutics [Member] | Contingent Consideration Payable Upon Achievement of Milestones [Member]

Business Combination, Contingent Consideration, Liability, Total

$ 26,000

Lowell Therapeutics [Member] | AcelRx Common Stock [Member]

Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Common Stock, Number (in shares)

9,009,538

Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Fixed Value per Share (in dollars per share)

$ 0.57284

Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Common Stock, Value

$ 5,200

Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares)

1,396,526

Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Value

$ 800

[1]	Recorded as Other long-term liabilities in the Condensed Consolidated Balance Sheets.
[2]	Recorded as In-process research and development asset in the Condensed Consolidated Balance Sheets.

Note 10 - Commitments and Contingencies

6 Months Ended

Jun. 30, 2022

Commitments and Contingencies Disclosure [Text Block]

10. Commitments and Contingencies

Litigation

On June 8, 2021, a securities class action complaint was filed in the U.S. District Court for the Northern District of California against the Company and two of its officers. The plaintiff is a purported stockholder of the Company. The complaint alleges that defendants violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 by making false and misleading statements and omissions of material fact about the Company’s disclosure controls and procedures with respect to its marketing of DSUVIA. The complaint seeks unspecified damages, interest, attorneys’ fees, and other costs. On December 16, 2021, the Court appointed co-lead plaintiffs. Plaintiffs’ amended complaint was filed on March 7, 2022. The amended complaint names the Company and three of its officers and continues to allege that defendants violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 by making false and misleading statements and omissions of material fact about the Company’s disclosure controls and procedures with respect to its marketing of DSUVIA. The amended complaint also alleges a violation of Section 20A of the Exchange Act against the individual defendants for alleged insider trading. On May 6, 2022, the Company filed a motion to dismiss the amended complaint with prejudice and briefing was complete on July 21, 2022. A hearing on the motion to dismiss is set for September 1, 2022.

On July 6, 2021, a purported shareholder derivative complaint was filed in the U.S. District Court for the Northern District of California. The complaint names ten of the Company’s officers and directors and asserts state and federal claims based on the same alleged misstatements as the shareholder class action complaint. On September 30, 2021, October 26, 2021, and November 17, 2021, three additional purported shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California. The complaints name nine of the Company’s officers and directors and also assert state and federal claims based on the same alleged misstatements as the shareholder class action complaint. All four complaints seek unspecified damages, attorneys’ fees, and other costs. On December 6, 2021, the Court entered an order consolidating all four actions and staying the consolidated action pending the outcome of any motion to dismiss the securities class action. Please see “Part II., Item 1A. Risk Factors—Risks of a General Nature—Litigation may substantially increase our costs and harm our business.”

The Company believes that these lawsuits are without merit and intends to vigorously defend against them. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

Note 12 - Stock-based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details) - Performance Shares [Member]	6 Months Ended
	Jun. 30, 2022
Expected term (in years) (Year)	6 years 3 months 18 days
Expected volatility	88.00%
Expected dividend rate	0.00%
Minimum [Member]
Risk-free interest rate	1.60%
Maximum [Member]
Risk-free interest rate	2.20%

Note 7 - Long-term Debt

6 Months Ended

Jun. 30, 2022

Long-Term Debt [Text Block]

7. Long-Term Debt

Loan Agreement with Oxford

On May 30, 2019, the Company entered into the Loan Agreement with Oxford. Under the Loan Agreement, the Lender made a term loan to the Company in an aggregate principal amount of $25.0 million, or the Loan, which was funded on May 30, 2019. The Loan Agreement requires that the Company always maintain unrestricted cash of not less than $5.0 million in accounts subject to control agreements in favor of the Lender, tested monthly as of the last day of the month.

In connection with the Loan Agreement, on May 30, 2019, the Company issued warrants to the Lender and its affiliates, or the Warrants, which are exercisable for an aggregate of 176,679 shares of the Company’s common stock with a per share exercise price of $2.83. The Warrants have been classified within stockholders’ deficit and accounted for as a discount to the loan by allocating the gross proceeds on a relative fair value basis.

As of June 30, 2022 and December 31, 2021, the accrued balance due under the Loan Agreement with Oxford was $9.4 million and $13.3 million, respectively. Interest expense related to the Loan Agreement was $0.3 million, $0.1 million of which represented amortization of the debt discount, and $0.7 million, $0.2 million of which represented amortization of the debt discount, for the three and six months ended June 30, 2022, respectively, while such interest expense was $0.6 million, $0.2 million of which represented amortization of the debt discount, and $1.2 million, $0.4 million of which represented amortization of the debt discount for the three and six months ended June 30, 2021, respectively.

Non-Interest Bearing Payments for the Construction of Leasehold Improvements

In August 2019, the Company entered into a Site Readiness Agreement, or SRA, with Catalent Pharma Solutions, LLC, or Catalent, in contemplation of entering into a commercial supply agreement for its product DSUVIAat a future date. Under the SRA, the Company is building out a suite within Catalent’s production facility in Kansas City. If additional equipment and facility modifications are required to meet the Company’s product needs, the Company may be required to contribute to the cost of such additional equipment and facility modifications. The Company has determined that it is the owner of the leasehold improvements related to the build-out which will be paid for in four installments of $0.5 million through July 2022. As of June 30, 2022 and December 31, 2021, the accrued balance under the SRA was $0.5 million, and $1.7 million of these leasehold improvements had been capitalized. The effective interest rate related to the payments at June 30, 2022 was 14.4%. The leasehold improvements are recorded as property and equipment, net, in our Condensed Consolidated Balance Sheets.

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2022	Aug. 05, 2022
Document Information [Line Items]
Entity Central Index Key	0001427925
Entity Registrant Name	ACELRX PHARMACEUTICALS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-35068
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-2193603
Entity Address, Address Line One	25821 Industrial Boulevard, Suite 400
Entity Address, City or Town	Hayward
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94545
City Area Code	650
Local Phone Number	216-3500
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ACRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		147,331,963

Note 8 - Leases (Details Textual) - USD ($)

Mar. 26, 2021

Jun. 30, 2022

Dec. 31, 2021

^[1]

Operating Lease, Right-of-Use Asset

$ 3,985,000

$ 4,302,000

Lease for Corporate Headquarters in Hayward, California [Member]

Lessee, Operating Lease, Term of Contract (Year)

2 years 3 months

Lessee, Operating Lease, Monthly Rent

$ 17,000

Lessee, Operating Lease, Abated Rent Period (Month)

1 month

Operating Lease, Right-of-Use Asset

$ 400,000

[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 9 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended		78 Months Ended
	May 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022
Liability related to sale of future royalties — beginning balance				$ 85,288		$ 0
Proceeds from sale of future royalties				0		61,184
Non-cash royalty revenue				0		(1,083)
Non-cash interest (income) expense recognized		$ (463)	$ (799)	(1,136)	$ (1,581)	24,051
Consideration paid for termination of Royalty Monetization	$ (100)			(100)		(100)
Gain on termination of liability related to sale of future royalties		(84,052)	$ 0	(84,052)	$ 0	(84,052)
Liability related to sale of future royalties as of June 30, 2022		$ 0		$ 0		$ 0

Note 4 - Asset Acquisition - Consideration for Acquisition (Details) (Parentheticals)	Jan. 07, 2022 shares
Lowell Therapeutics [Member]
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares)	1,396,526

Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Cash and cash equivalent, fair value		$ 12,663
Total cash, cash equivalents and restricted cash	$ 20,165	12,663	$ 26,327	$ 27,274
Total cash, cash equivalents, restricted cash and short-term investments, amortized cost	27,923	51,630
Total cash, cash equivalents, restricted cash and short-term investments, fair value	27,923	51,630
Marketable Securities [Member]
Short-term investment, amortized Cost	7,758	38,967
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Short-term investment, fair value	7,758	38,967
Commercial Paper [Member] \| Marketable Securities [Member]
Short-term investment, amortized Cost	7,758	29,504
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Short-term investment, fair value	7,758	29,504
Corporate Debt Securities [Member] \| Marketable Securities [Member]
Short-term investment, amortized Cost		9,463
Gross Unrealized Gains		0
Gross Unrealized Losses		0
Short-term investment, fair value		9,463
Cash and Cash Equivalents [Member] \| Cash [Member]
Cash, amortized cost	2,637	1,443
Cash and cash equivalent, fair value	2,637	1,443
Cash and Cash Equivalents [Member] \| Money Market Funds [Member]
Cash and cash equivalent, fair value	1,150	2,822
Money market funds, amortized cost	1,150	2,822
Cash and Cash Equivalents [Member] \| Commercial Paper [Member]
Cash and cash equivalent, fair value	16,378	8,398
Commercial paper, amortized cost	$ 16,378	$ 8,398

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Total

Balance (in shares) at Dec. 31, 2020

98,812,008

Balance at Dec. 31, 2020

$ 98

$ 382,637

$ (438,485)

$ (55,750)

Issuance of common stock upon vesting of restricted stock units (in shares)

$ 0

1,089

404,172

Issuance of common stock upon vesting of restricted stock units

$ 0

(249)

Issuance of common stock upon ESPP purchase (in shares)

183,132

Issuance of common stock upon ESPP purchase

$ 0

192

Net proceeds from issuance of common stock in connection with equity financings (in shares)

$ 0

(8,956)

19,701,562

Net proceeds from issuance of common stock in connection with equity financings

$ 20

36,340

36,360

Issuance of common stock upon exercise of stock options (in shares)

2,125

Issuance of common stock upon exercise of stock options

$ 0

Balance (in shares) at Mar. 31, 2021

119,102,999

Balance at Mar. 31, 2021

$ 118

420,011

(447,441)

(27,312)

Balance (in shares) at Dec. 31, 2020

98,812,008

Balance at Dec. 31, 2020

$ 98

382,637

(438,485)

(55,750)

Balance (in shares) at Jun. 30, 2021

(18,807)

119,179,806

Balance at Jun. 30, 2021

$ 119

421,184

(457,292)

(35,989)

Balance (in shares) at Mar. 31, 2021

119,102,999

Balance at Mar. 31, 2021

$ 118

420,011

(447,441)

(27,312)

Issuance of common stock upon vesting of restricted stock units (in shares)

$ 0

1,172

74,438

Issuance of common stock upon vesting of restricted stock units

$ 0

Issuance of common stock upon exercise of stock options (in shares)

$ 0

(9,851)

2,369

Issuance of common stock upon exercise of stock options

$ 1

Balance (in shares) at Jun. 30, 2021

119,179,806

Balance at Jun. 30, 2021

$ 119

421,184

(457,292)

(35,989)

Balance (in shares) at Dec. 31, 2021

136,819,647

Balance at Dec. 31, 2021

$ 137

437,554

(473,584)

(35,893)

^[1]

Issuance of common stock upon vesting of restricted stock units (in shares)

$ 0

783

515,393

Issuance of common stock upon vesting of restricted stock units

$ 0

(58)

Issuance of common stock in connection with asset acquisition (in shares)

9,620,532

Issuance of common stock in connection with asset acquisition

$ 10

5,501

5,511

Issuance of common stock upon ESPP purchase (in shares)

153,435

Issuance of common stock upon ESPP purchase

$ 0

Balance (in shares) at Mar. 31, 2022

$ 0

(8,674)

147,109,007

Balance at Mar. 31, 2022

$ 147

443,838

(482,258)

(38,273)

Balance (in shares) at Dec. 31, 2021

136,819,647

Balance at Dec. 31, 2021

$ 137

437,554

(473,584)

(35,893)

^[1]

Issuance of common stock upon exercise of stock options (in shares)

$ 61,989

(0)

Balance (in shares) at Jun. 30, 2022

147,331,963

Balance at Jun. 30, 2022

$ 147

444,591

(411,595)

$ 33,143

Balance (in shares) at Mar. 31, 2022

147,109,007

Balance at Mar. 31, 2022

$ 147

443,838

(482,258)

(38,273)

Issuance of common stock upon vesting of restricted stock units (in shares)

$ 0

753

222,956

Issuance of common stock upon vesting of restricted stock units

$ 0

Balance (in shares) at Jun. 30, 2022

$ 0

70,663

147,331,963

Balance at Jun. 30, 2022

$ 147

$ 444,591

$ (411,595)

$ 33,143

[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 12 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Stock-based compensation expense	$ 753	$ 1,172	$ 1,536	$ 2,261
Cost of Sales [Member]
Stock-based compensation expense	16	21	35	43
Research and Development Expense [Member]
Stock-based compensation expense	153	200	327	381
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 584	$ 951	$ 1,174	$ 1,837

Note 12 - Stock-based Compensation - Option Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Outstanding (in shares) \| shares	14,284,050
Outstanding (in dollars per share) \| $ / shares	$ 2.99
Granted (in shares) \| shares	2,123,650
Granted, weighted-average exercise price (in dollars per share) \| $ / shares	$ 0.40
Forfeited (in shares) \| shares	(552,745)
Forfeited, weighted-average exercise price (in dollars per share) \| $ / shares	$ 1.37
Expired (in shares) \| shares	(812,693)
Expired, weighted-average exercise price (in dollars per share) \| $ / shares	$ 3.31
Exercised (in shares) \| shares	0
Exercised, weighted-average exercise price (in dollars per share) \| $ / shares	$ 0
Outstanding (in shares) \| shares	15,042,262
Outstanding, weighted-average exercise price (in dollars per share) \| $ / shares	$ 2.67
Outstanding, weighted-average remaining contractual life (Year)	5 years 9 months 18 days
Outstanding, aggregate intrinsic value \| $	$ 0
Vested and exercisable options (in shares) \| shares	10,473,947
Vested and exercisable options, weighted-average exercise price (in dollars per share) \| $ / shares	$ 3.31
Vested and exercisable options, weighted-average remaining contractual life (Year)	4 years 6 months
Vested and exercisable options, aggregate intrinsic value \| $	$ 0
Vested and expected to vest (in shares) \| shares	15,042,262
Vested and expected to vest, weighted-average exercise price (in dollars per share) \| $ / shares	$ 2.67
Vested and expected to vest, weighted-average remaining contractual life (Year)	5 years 9 months 18 days
Vested and expected to vest, aggregate intrinsic value \| $	$ 0

Note 5 - Property and Equipment, Net

6 Months Ended

Jun. 30, 2022

Property, Plant and Equipment Disclosure [Text Block]

5. Property and Equipment, Net

Property and equipment, net consist of the following (in thousands):

	Balance as of
	June 30, 2022			December 31, 2021
Laboratory equipment	$	4,406		$	4,406
Leasehold improvements		5,838			5,838
Computer equipment and software		1,589			1,589
Construction in process		9,459			13,805
Tooling		826			826
Furniture and fixtures		250			250
		22,368			26,714
Less accumulated depreciation and amortization		(11,293	)		(10,786	)
Property and equipment, net	$	11,075		$	15,928

As of June 30, 2022, the Company decided to realign its cost structure from a focus on commercialization to a focus on advancing our recently acquired late-stage development pipeline, namely the pre-filled syringes and Niyad product candidates. As a result, the Company also decided to not focus any development resources on Zalviso in the United States and does not expect to resubmit the Zalviso NDA in the foreseeable future. In addition, due to the termination of the agreements with Grünenthal for Zalviso in Europe and the related withdrawal of the Marketing Authorization in Europe in July 2022, the Company does not expect any revenues from Zalviso in Europe in the foreseeable future. Accordingly, the Company determined that it is no longer probable that it will realize the future economic benefit associated with the costs of the Zalviso-related purchased equipment and manufacturing-related facility improvements the Company has made at its contract manufacturer and, therefore, recorded a non-cash impairment charge of $4.9 million to the Zalviso-related assets for the three and six months ended June 30, 2022. The impairment charge was recorded as operating expense in the Condensed Consolidated Statement of Operations. Depreciation and amortization expense was $0.2 million and $0.5 million for the three and six months ended June 30, 2022, respectively, and $0.3 million and $0.5 million for the three and six months ended June 30, 2022, respectively.

Note 8 - Leases

6 Months Ended

Jun. 30, 2022

Lessee, Operating Leases [Text Block]

8. Leases

Office Lease

On March 26, 2021, the Company entered into a Sublease Agreement to sublet space for its new corporate headquarters, located at 25821 Industrial Boulevard, Hayward, California. The Sublease Agreement commencement date was April 1, 2021. The Sublease Agreement is for a period of two years and three months with monthly rental payments of $17,000, including one month of abated rent. On the lease commencement date, the Company recognized an operating lease right-of-use asset in the amount of $0.4 million.

Contract Manufacturing Leases

The Company has entered into commercial supply manufacturing services agreements related to Zalviso and DSUVIA containing fixed fees which it has determined are in-substance lease payments. For additional information on these agreements, refer to Note 9 “Leases” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

The components of lease expense are presented in the following table (in thousands):

	Three Months Ended June 30,					Six Months Ended June 30,
	2022		2021			2022		2021
Operating lease costs	$	343	$	440		$	686	$	780
Gain on derecognition of operating lease		—		—			—		(522	)
Sublease income		—		(50	)		—		(199	)
Loss on termination of sublease		—		331			—		331
Net lease costs	$	343	$	721		$	686	$	390

The weighted average remaining lease term and discount rate related to the operating leases are presented in the following table:

	June 30, 2022			June 30, 2021
Weighted-average remaining lease term – operating leases (years)	4.57			5.41
Weighted-average remaining discount rate – operating leases		12.8	%		12.8	%

Maturities of lease liabilities as of June 30, 2022 are presented in the following table (in thousands):

Year:
2022 (remaining six months)	$	921
2023		1,344
2024		1,040
2025		1,040
2026		1,040
Thereafter		415
Total future minimum lease payments		5,800
Less imputed interest		(1,299	)
Total	$	4,501

Reported as:
Operating lease liabilities	$	4,501
Operating lease liabilities, current portion		(1,142	)
Operating lease liabilities, net of current portion	$	3,359

Note 9 - Liability Related to Sale of Future Royalties

6 Months Ended

Jun. 30, 2022

Cash and cash equivalents

9. Liability Related to Sale of Future Royalties

On September 18, 2015, the Company entered into the Royalty Monetization with PDL for which it received gross proceeds of $65.0 million. Under the Royalty Monetization, PDL was to receive 75% of the European royalties under the Amended License Agreement with Grünenthal, as well as 80% of the first four commercial milestones worth $35.6 million (or 80% of $44.5 million), up to a capped amount of $195.0 million over the life of the arrangement.

The Company periodically assessed the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments were greater or less than the Company’s initial estimates or the timing of such payments is materially different than its original estimates, the Company prospectively adjusted the amortization of the liability and the effective interest rate. During the three months ended June 30, 2020, Grünenthal notified the Company that it was terminating the Amended License Agreement, effective November 13, 2020. On August 31, 2020, PDL sold its royalty interest for Zalviso to SWK Funding, LLC, or SWK, under the Royalty Monetization. The terms of the Grünenthal Agreements were extended to May 12, 2021 to enable Grünenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on May 12, 2021.

On May 31, 2022, the Company entered into the Termination Agreement with SWK to fully terminate the Royalty Monetization for which the Company paid cash consideration of $0.1 million, and neither PDL nor SWK retains any further interest in the Royalty Monetization. Accordingly, effective May 31, 2022, the Royalty Monetization is no longer reflected on the Company’s consolidated financial statements or other records as a sale of assets to PDL or SWK and all security interests and other liens of every type held by the parties to the Royalty Monetization have been terminated and automatically released without further action by any party. The $84.1 million gain on extinguishment of the liability related to the sale of future royalties is recognized in the Condensed Consolidated Statements of Operations as Other Income.

The effective interest income rate for each of the three- and six-month periods ended June 30, 2022, was approximately 3.2%. The effective interest income rate for each of the three- and six-month periods ended June 30, 2021, was approximately 3.6%.

The following table shows the activity within the liability account related to the sale of future royalties for the six months ended June 30, 2022 and the period from inception on September 18, 2015 to June 30, 2022 (in thousands):

	Six months ended June 30, 2022			Period from inception to June 30, 2022
Liability related to sale of future royalties — beginning balance	$	85,288		$	—
Proceeds from sale of future royalties		—			61,184
Non-cash royalty revenue		—			(1,083	)
Non-cash interest (income) expense recognized		(1,136	)		24,051
Consideration paid for termination of Royalty Monetization		(100	)		(100	)
Gain on termination of liability related to sale of future royalties		(84,052	)		(84,052	)
Liability related to sale of future royalties as of June 30, 2022	$	—		$	—

As mentioned above, the Royalty Monetization was terminated on May 31, 2022.

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands

Jun. 30, 2022

Dec. 31, 2021

^[1]

Current Assets:

$ 15,165

$ 7,663

Restricted cash

5,000

Short-term investments

7,758

38,967

Accounts receivable, net

364

160

Inventories, net

901

1,111

Prepaid expenses and other current assets

2,809

2,588

Total current assets

31,997

50,489

Operating lease right-of-use assets

3,985

4,302

Property and equipment, net

11,075

15,928

In-process research and development asset

8,819

Other assets

257

2,174

Restricted cash, net of current portion

5,000

Total Assets

56,133

77,893

Current Liabilities:

Accounts payable

2,400

2,121

Accrued and other liabilities

4,260

6,524

Long-term debt, current portion

9,887

8,796

Operating lease liabilities, current portion

1,142

1,068

Total current liabilities

17,689

18,509

Long-term debt, net of current portion

5,007

Deferred revenue, net of current portion

1,093

1,151

Operating lease liabilities, net of current portion

3,359

3,750

85,288

Other long-term liabilities

849

Total liabilities

22,990

113,786

Commitments and Contingencies (Note 10)

Stockholders’ Equity (Deficit):

Common stock, $0.001 par value—200,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 147,331,963 and 136,819,647 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively

147

137

Additional paid-in capital

444,591

437,554

Accumulated deficit

(411,595)

(473,584)

Total stockholders’ equity (deficit)

33,143

(35,893)

Total Liabilities and Stockholders’ Equity (Deficit)

$ 56,133

$ 77,893

[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 3 - Inventories, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
ZALVISO [Member]
Inventory Write-down	$ 0	$ 0	$ 0	$ 100

Note 13 - Net Income (Loss) Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
RSU's, ESPP, and Employee Stock Options [Member]
Antidilutive securities (in shares)	16,520,200	16,907,412	16,463,459	16,907,412
Warrant [Member]
Antidilutive securities (in shares)	17,676,679	176,679	17,676,679	176,679

Note 13 - Net Income (Loss) Per Share of Common Stock - Computation of Basic and Diluted Net Income (Loss) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Net income (loss)	$ 70,663	$ (8,674)	$ (9,851)	$ (8,956)	$ 61,989	$ (18,807)
Weighted average shares outstanding — basic (in shares)	147,139,032		119,120,040		146,385,577	116,204,492
Dilutive effect of RSUs (in shares)	70,033		0		34,860	0
Weighted average shares outstanding — diluted (in shares)	147,209,065		119,120,040		146,420,437	116,204,492
Net income (loss) per share — basic (in dollars per share)	$ 0.48		$ (0.08)		$ 0.42	$ (0.16)
Net income (loss) per share — diluted (in dollars per share)	$ 0.48		$ (0.08)		$ 0.42	$ (0.16)

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Note 14 - Subsequent Event

6 Months Ended

Jun. 30, 2022